Côd QR

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

BackgroundNon‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low‐density lipoprotein cholesterol alone. US and European lipid management guidelines support non‐HDL‐C and apoB as targets for lipid‐l...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Harold E. Bays, Lawrence A. Leiter, Helen M. Colhoun, Desmond Thompson, Laurence Bessac, Robert Pordy, Peter P. Toth
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wiley 2017-08-01
Cyfres:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Pynciau:
alirocumab
apolipoprotein B
cholesterol‐lowering
hypercholesterolemia
non‐high‐density lipoprotein cholesterol
PCSK9
Mynediad Ar-lein:https://www.ahajournals.org/doi/10.1161/JAHA.117.005639
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg